Cogent Biosciences released quarterly earnings results that came in below consensus expectations on an earnings-per-share ...

Suchandrima Bhowmik has written over 300 articles on various health conditions, medical news, and recent breakthroughs. Her work appears in several publications, including Medical News Today, ...

Ocugen has reported preliminary phase 2 data on its eye disease gene therapy, providing more evidence that the candidate may outperform existing treatments from Apellis Pharmaceuticals and Astellas ...

Carrie Madormo, RN, MPH, is a health writer. She has over a decade of experience as a registered nurse, practicing in a variety of fields, such as pediatrics, oncology, chronic pain, and public health ...

The NFL has announced its International Player Pathway (IPP) program Class of 2026, featuring 13 athletes representing 10 nations around the world. Established in 2017, the IPP program identifies ...

UCSF is preparing to accept its latest batch of trainees as part of a $14 million workforce-development initiative for young San Francisco adults. Michael Jones, the program director at Career ...

The complement system is an innate immune response that leads to increased inflammation. The drug pegcetacoplan—a complement inhibitor—was approved for medical use in the United States in 2021 to ...

The Pixar Era kicked off 30 years ago with the first installment of the popular franchise. It’s given us countless hits, but something has also been lost. By Maya Phillips There are so many ways of ...

OWENS CROSS ROAD, Ala. (WHNT) — The Owens Cross Roads City Council has voted to pursue legal action against a mental health facility operating in the city. During a special-called meeting on Thursday, ...

In a highly anticipated article, FDA officials Vinay Prasad, M.D., and Martin Makary, M.D., outlined a novel regulatory pathway that could trigger a seismic shift in how bespoke gene editing therapies ...

SAN FRANCISCO -- The investigational complement-targeting agent claseprubart was safe and led to significant improvements in generalized myasthenia gravis (MG), the phase II MaGic trial showed. The ...